2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle C
Technology and Procedures, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Treatment Considerations, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

552 Single cell whole genome sequencing reveals genomic instability as a driver of tumor evolution and resistance to therapy in multiple myeloma

Andrew McPherson, PhD, Sarun Sereewattanawoot, MD, PhD2, Matthew Myers, PhD3, Eliyahu Havasov4, Huiyoung Yun, PhD5, Kylee Maclachlan, MD, PhD6, Neha Korde, MD7, Gareth Morgan, MD, PhD8, Nizar Bahlis, MD9, Ross Firestone, MD/PhD10, Marta Chesi, PhD11, Mariano Arribas12, Gregory Ahmann, BS13, J Erin Wiedmeier-Nutor, MD,MPH14, Rafael Fonseca, MD15, P. Leif Bergsagel, MD16, Saad Z. Usmani, MD17, Sohrab Shah, PhD18, Francesco Maura, MD19
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
9 University of Calgary, Calgary, Alberta, Canada
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Mayo Clinic, Phoenix, Arizona, United States
12 Mayo Clinic, Phoenix, Arizona, United States
13 Mayo Clinic, Phoenix, Arizona, United States
14 Mayo Clinic, Phoenix, Arizona, United States
15 Mayo Clinic, Phoenix, Arizona, United States
16 Mayo Clinic, Phoenix, Arizona, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States

BACKGROUND: Multiple Myeloma (MM) is a malignancy driven by the accumulation of genomic alterations over time, including copy number alteration (CNAs), structural variants (SVs), and single nucleotide variants (SNVs). However, this evolution has been mostly characterized using bulk whole-genome sequencing (WGS) and single-cell RNA or single-cell CNA approaches. None of these approaches can capture all key genomic events at single-cell resolution, limiting our understanding of MM evolution.

AIM: To characterize the single-cell WGS landscape of MM evolution and its impact on response to immunotherapies.

METHODS: We applied the DLP+ single-cell whole-genome sequencing (scWGS) platform to CD138+ plasma cells from a  cohort of 12 newly diagnosed MM (NDMM) samples and 2 relapsed MM (RRMM) samples. DLP+ is a unique scWGS platform that enables accurate detection of CNAs in individual cells and infers clonal SNVs, indels, and SVs by aggregating sparse sequences from groups of genetically similar cells. In addition, DLP+ can resolve complex events including chromothripsis, and allows extraction of allelic genotypes, enabling distinction between alleles. By integrating all these data, DLP+ enables accurate phylogenetic tree reconstruction and assessment of ongoing genomic instability (McPherson et al. Nature 2025). 96 MM samples previously sequenced using the 10x Single Cell CNA kit were used as a validation set.

RESULTS: Analyzing 5454 cells (390 cells per sample), we reconstructed the phylogenetic tree of each patient using haplotype-specific CNAs. Tree structures were characterized by variants shared by all cells (most recent common ancestor, MRCA), subclonal variants shared by clusters of cells, and cell-specific variants encompassing genomic events occurring at the single-cell level. This unique resolution revealed a bimodal distribution of MM patients irrespective of their IGH translocation status. The first group was characterized by genomically stable tumors, with minimal diversification at both subclonal and cell-specific levels. The second group showed an opposite landscape characterized by patterns of genomic instability, both previously reported and novel. Among the known patterns, we observed a major subclonal diversification, high burden of post-gain deletions, whole-genome doubling, and convergent evolution with different cells independently acquiring the same chromosomal alterations, occasionally involving different alleles. We observed patterns of genomic instability that had not been previously reported in MM, including telomeric erosion, characterized by variable-length copy number losses extending from the same telomeric regions across different single tumor cells. Finally, we observed several instances of complex SVs, including chromothripsis-induced instability that appeared to be resolved independently into different structures, generating heterogeneity across individual cells.

To assess the significance of these events, we developed a method that quantifies ancestral, clone-specific, and cell-specific CNAs for each sample, where ancestral events refer to changes shared by all malignant cells (MRCA), subclones, and clone-specific events, enabling us to capture the key hallmarks of genomic instability in our cohort. Using this metric, we categorized NDMM patients with available clincal data into genomically stable (n=7) and unstable (n=4) groups. All patients in the latter group never achieved MRD negativity and experienced progression within the first 30 months after treatment with daratumumab, lenalidomide, bortezomib or carfilzomib, and dexamethasone. In contrast, none of the genomically stable patients progressed after 7 years. To validate these findings, we leveraged 10X Single Cell CNA data from 7 patients treated with anti-BCMA bispecific antibodies. While less reliable than DLP+, we were able to observe patterns of genomic instability in these patients resembling those seen with DLP+. Patients with genomic instability all rapidly progressed within the first 6 months, while those with genomically stable tumors did not experience any progression, except for one patient who relapsed with a mutation in the BCMA extracellular domain.

CONCLUSION: With DLP+ scWGS platform, we provided clear evidence of genomic instability in NDMM and RRMM, highlighting known and novel hallmarks of this phenomenon. We further quantified the degree of instability and associated it with worse outcomes in the era of immunotherapy.

Sarun Sereewattanawoot, MD, PhD: No relevant conflicts of interest to declare.